Low dose naltrexone (LDN) has a favorable safety profile based on available clinical evidence. No severe adverse events have been reported across studies lasting up to 14 months, and the side effects that do occur are typically mild and often resolve on their own. That said, LDN does have real contraindications and interaction risks that matter, particularly if you take opioid medications or have liver disease.
What LDN Is and How It Differs From Standard Naltrexone
Naltrexone at its FDA-approved dose of 50 mg per day is used to treat alcohol and opioid dependence. Low dose naltrexone refers to doses between 0.1 and 4.5 mg per day, most commonly around 4.5 mg. At these much smaller doses, the drug appears to work differently than it does at full strength. Rather than simply blocking opioid receptors around the clock, a brief, low-level blockade triggers the body to increase production of its own natural painkillers (beta-endorphin) and reduce inflammation by calming immune cells in the central nervous system called microglia.
LDN is not FDA-approved for any condition at these low doses. It is prescribed off-label, typically by compounding pharmacies, for chronic pain conditions like fibromyalgia, autoimmune diseases, and other inflammatory conditions. This off-label status means large-scale safety trials are limited, but the evidence that does exist is reassuring.
Common Side Effects
Side effects are relatively common but rarely serious. In a real-world retrospective study of chronic pain patients, about half experienced at least one adverse effect. The most frequently reported was nausea, occurring in 18 patients, and roughly two-thirds of those cases were transient. Other common effects included fatigue (7 cases), vivid dreams (6), insomnia (6), headache (5), anxiety (3), and dizziness (2).
Vivid dreams and sleep disturbances are particularly characteristic of LDN. These tend to be most noticeable in the first few weeks and often fade with continued use. If they persist, reducing the dose can help. Some practitioners recommend taking LDN in the morning rather than at bedtime to minimize sleep disruption.
What Longer Studies Show
A systematic review of LDN for fibromyalgia examined studies ranging from 3 weeks to 14 months in duration, with follow-up periods extending as long as 15 months after treatment ended. Of the studies that specifically evaluated safety (78% of those included), none reported severe adverse events. One 13-month study noted only transient insomnia and vivid dreams. Another study with a 15-month follow-up reported no side effects at all related to LDN.
These timelines are encouraging but still relatively short compared to how long most people take LDN in practice, which can be years. The absence of serious safety signals over 14 months is meaningful, but there are no published studies tracking outcomes over five or ten years of continuous use.
Liver Safety
The naltrexone package insert carries a warning about dose-dependent liver toxicity, which understandably raises concern. This warning is based on studies using doses far higher than LDN, typically 50 mg or more per day. At those doses, elevated liver enzymes have occasionally been observed, though even one study of high-dose naltrexone in 41 patients found no changes in liver enzyme levels.
At LDN doses of 0.1 to 4.5 mg, the risk to the liver appears to be minimal. Still, naltrexone is formally contraindicated in people with acute hepatitis or liver failure. If you have active liver disease, the decision to use LDN requires careful consideration of liver function.
Dependence and Withdrawal
LDN does not cause physical dependence. It is an opioid antagonist, meaning it blocks opioid receptors rather than activating them. There is no evidence of withdrawal symptoms when stopping LDN. In clinical trials of very low dose naltrexone, researchers found no treatment-related adverse events and no episodes of medication-precipitated withdrawal. People who stop taking LDN may notice a return of whatever symptoms the medication was managing, but this reflects the loss of a therapeutic effect, not chemical dependence.
The Opioid Interaction Risk
This is the most significant safety concern with LDN. Because naltrexone blocks opioid receptors, taking it while opioids are still in your system can trigger acute withdrawal, which is intensely uncomfortable and potentially dangerous. Current guidance recommends stopping all opioid therapy for at least ten days before starting naltrexone at any dose.
The interaction works in both directions. If you’ve been taking LDN and then need opioid pain medication (after surgery, for example, or due to an injury), your sensitivity to opioids may be heightened. This means a standard dose could produce an unexpectedly strong response. Anyone taking LDN should make sure their medical team knows, especially before any procedure where opioid pain relief might be needed. The same caution applies to buprenorphine and methadone, which should not be combined with naltrexone.
Who Should Not Take LDN
Based on established naltrexone contraindications, LDN should be avoided if you:
- Currently use opioids of any kind, including prescription painkillers, buprenorphine, or methadone
- Have acute hepatitis or liver failure
- Expect to need opioid pain medication within the next 7 to 10 days
- Have a known allergy to naltrexone, naloxone, or nalmefene
- Are in active alcohol withdrawal, as FDA labeling recommends waiting until acute withdrawal symptoms have resolved
Pregnancy and Breastfeeding
Data on LDN during pregnancy is extremely limited, and no firm safety conclusions can be drawn. During breastfeeding, the picture is somewhat clearer. Limited studies show that naltrexone passes into breast milk in very small amounts. In one case, an exclusively breastfed infant would have received roughly 0.86% of the mother’s weight-adjusted dose, and the infant’s blood showed undetectable levels of both naltrexone and its active byproduct. A breastfed infant whose mother took 50 mg daily (well above LDN range) was reportedly healthy with no drug-related adverse effects. Based on this limited evidence, naltrexone during breastfeeding is not considered a reason to stop nursing.
Dosing Considerations That Affect Safety
Most practitioners start LDN at a low dose, often around 1 mg or less, and gradually increase to a target between 1.5 and 4.5 mg per day. This slow titration helps minimize side effects like nausea and sleep disruption. Recent observational research suggests that the right dose varies considerably from person to person, ranging anywhere from 0.1 to 6.0 mg per day. A fixed 4.5 mg dose for everyone may not be ideal, and some people do better at lower amounts.
Because LDN is compounded rather than commercially manufactured at these doses, the quality of the preparation matters. Compounding pharmacies vary in their standards, and using a reputable pharmacy that tests its products helps ensure you’re getting an accurate, consistent dose.